BMO Capital Maintains Market Perform on Amgen, Lowers Price Target to $415

BMO Capital analyst Evan David Seigerman has maintained a Market Perform rating on Amgen (NASDAQ: AMGN) while lowering the price target from $450 to $415. This adjustment reflects a revised outlook on the company's performance.